Search

Harmony Biosciences Holdings Inc

Avatud

SektorTervishoid

39.61 0.35

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

38.85

Max

39.61

Põhinäitajad

By Trading Economics

Sissetulek

43M

75M

Müük

46M

261M

P/E

Sektori keskmine

12.42

57.002

Aktsiakasum

1.28

Kasumimarginaal

28.87

Töötajad

293

EBITDA

47M

96M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+5.34% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

210M

2.3B

Eelmine avamishind

39.26

Eelmine sulgemishind

39.61

Uudiste sentiment

By Acuity

50%

50%

135 / 340 Pingereas Healthcare

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. aug 2026, 19:21 UTC

Harmony Biosciences Holdings Inc. is trading higher today, continuing its upward trajectory since Monday's close amid broader market trends and rising oil prices.

10. aug 2026, 19:46 UTC

Harmony Biosciences Holdings Inc is trading higher, continuing its upward trend since Friday. The stock remains above its 20-day moving average.

7. aug 2026, 20:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower amid broader market declines and decreasing Treasury yields following recent economic data.

6. aug 2026, 23:51 UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

5. aug 2026, 20:03 UTC

Social Media
Event
News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

4. aug 2026, 20:04 UTC

Social Media
News
Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

3. aug 2026, 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1. aug 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31. juuli 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28. juuli 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27. juuli 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24. juuli 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22. juuli 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21. juuli 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

5.34% tõus

12 kuu keskmine prognoos

Keskmine 41.63 USD  5.34%

Kõrge 55 USD

Madal 30 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

3

Osta

4

Hoia

1

Müü

Sentiment

By Acuity

135 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat